Dupilumab in the Management of Moderate-to-Severe Atopic Dermatitis: an Evidence-Based Review of Efficacy, Quality of Life Impact, and Safety Profile

Szymon Smereka; Wiktor Jabłoński; Julia Raszewska; Paulina Osyra; Natalia Wolińska; Jan Frycz

doi:10.5114/dr.2025.153227

eISSN: 2084-9893
ISSN: 0033-2526

Dermatology Review/Przegląd Dermatologiczny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

2/2025
vol. 112

Send email

Copy url:

abstract:

Review article

Dupilumab in the Management of Moderate-to-Severe Atopic Dermatitis: an Evidence-Based Review of Efficacy, Quality of Life Impact, and Safety Profile

Szymon Smereka

¹

,

Wiktor Jabłoński

²

,

Julia Raszewska

³

,

Paulina Osyra

¹

,

Natalia Wolińska

⁴

,

Jan Frycz

³

G. Narutowicz Municipal Specialist Hospital, Krakow, Poland
Stefan Żeromski Specialist Hospital, Krakow, Poland
Andrzej Frycz Modrzewski Krakow University, Krakow, Poland
Beskid Oncology Center – St. John Paul II Municipal Hospital, Bielsko-Biala, Poland

Dermatol Rev/Przegl Dermatol 2025, 112, 80-82

DOI: https://doi.org/10.5114/dr.2025.153227

Online publish date: 2025/06/30

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Smereka S, Jabłoński W, Raszewska J, Osyra P, Wolińska N, Frycz J. Dupilumab in the Management of Moderate-to-Severe Atopic Dermatitis: an Evidence-Based Review of Efficacy, Quality of Life Impact, and Safety Profile. Dermatology Review/Przegląd Dermatologiczny. 2025;112(2):80-82. doi:10.5114/dr.2025.153227.

APA

Smereka, S., Jabłoński, W., Raszewska, J., Osyra, P., Wolińska, N.,  & Frycz, J. (2025). Dupilumab in the Management of Moderate-to-Severe Atopic Dermatitis: an Evidence-Based Review of Efficacy, Quality of Life Impact, and Safety Profile. Dermatology Review/Przegląd Dermatologiczny, 112(2), 80-82. https://doi.org/10.5114/dr.2025.153227

Chicago

Smereka, Szymon, Wiktor Jabłoński, Julia Raszewska, Paulina Osyra, Natalia Wolińska,  and Jan Frycz. 2025. "Dupilumab in the Management of Moderate-to-Severe Atopic Dermatitis: an Evidence-Based Review of Efficacy, Quality of Life Impact, and Safety Profile". Dermatology Review/Przegląd Dermatologiczny 112 (2): 80-82. doi:10.5114/dr.2025.153227.

Harvard

Smereka, S., Jabłoński, W., Raszewska, J., Osyra, P., Wolińska, N.,  and Frycz, J. (2025). Dupilumab in the Management of Moderate-to-Severe Atopic Dermatitis: an Evidence-Based Review of Efficacy, Quality of Life Impact, and Safety Profile. Dermatology Review/Przegląd Dermatologiczny, 112(2), pp.80-82. https://doi.org/10.5114/dr.2025.153227

MLA

Smereka, Szymon et al. "Dupilumab in the Management of Moderate-to-Severe Atopic Dermatitis: an Evidence-Based Review of Efficacy, Quality of Life Impact, and Safety Profile." Dermatology Review/Przegląd Dermatologiczny, vol. 112, no. 2, 2025, pp. 80-82. doi:10.5114/dr.2025.153227.

Vancouver

Smereka S, Jabłoński W, Raszewska J, Osyra P, Wolińska N, Frycz J. Dupilumab in the Management of Moderate-to-Severe Atopic Dermatitis: an Evidence-Based Review of Efficacy, Quality of Life Impact, and Safety Profile. Dermatology Review/Przegląd Dermatologiczny. 2025;112(2):80-82. doi:10.5114/dr.2025.153227.

PlumX metrics:

Atopic dermatitis is a chronic, inflammatory skin disease that significantly impacts patients’ quality of life. Its persistent symptoms such as pruritus, skin barrier dysfunction, and associated comorbidities can be debilitating. Conventional treatments for atopic dermatitis, including systemic corticosteroids and immunosuppressants, are often associated with a high risk of adverse effects, particularly with long-term use, which limits their application due to patient safety concerns. In contrast, dupilumab, a monoclonal antibody that blocks interleukin-4 and interleukin-13 by targeting the IL-4 receptor alpha, has emerged as a promising therapeutic option, as it effectively disrupts the key pathophysiological pathways driving atopic dermatitis. This paper presents a review of the efficacy, safety, and impact on quality of life associated with treatment using dupilumab. The information is derived from data obtained through clinical trials, open-label extension studies, and real-world assessments. The data from the aforementioned studies demonstrate significant improvements in disease progression, including symptom relief and, importantly, enhanced quality of life as reported by patients. Additionally, dupilumab exhibits a favorable safety profile, characterized by low rates of serious adverse events; however, occurrences of conjunctivitis and injection site reactions have also been documented. This review offers a comprehensive analysis of dupilumab’s role in the treatment of atopic dermatitis, highlighting its suitability for long-term use as well as its efficacy in patients who exhibit an inadequate response to conventional therapies.

keywords:

atopic dermatitis, dupilumab, dermatology

Indeks osobowy

Dupilumab in the Management of Moderate-to-Severe Atopic Dermatitis: an Evidence-Based Review of Efficacy, Quality of Life Impact, and Safety Profile

Szymon Smereka 1 , Wiktor Jabłoński 2 , Julia Raszewska 3 , Paulina Osyra 1 , Natalia Wolińska 4 , Jan Frycz 3

atopic dermatitis, dupilumab, dermatology

Szymon Smereka

¹

,

Wiktor Jabłoński

²

,

Julia Raszewska

³

,

Paulina Osyra

¹

,

Natalia Wolińska

⁴

,

Jan Frycz

³